CAS:881681-00-1TAK-438 free base

您的位置 : 首页 / Membrane Transporter/Ion Channel / Potassium Channel / TAK-438 Free Base

TAK-438 Free Base TAK-438 free base Cat No. FB06892Cas No. 881681-00-1

TAK-438 Free Base is a blocker of potassium-competitive proton pump that reversibly inhibits H+/K+ ATPase with IC50 of 17 nM at pH 6.5 while do not affect on Na+/K+ ATPase activity. It has been used to treatment of erosive esophagitis and gastroduodenal ulcer.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.8953 mL
- 14.4763 mL
- 28.9527 mL
- 5 mM
- 0.5791 mL
- 2.8953 mL
- 5.7905 mL
- 10 mM
- 0.2895 mL
- 1.4476 mL
- 2.8953 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

881681-00-1

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C17H16FN3O2S

运输

蓝冰

分子量

345.39

别名

溶解度

DMSO	210.0 mg/mL (608.0 mM)
Water	insoluble

动物实验配方

靶点数据

生物活性

靶点 H+/K+ ATPase

IC50:19nM(pH6.5)
描述TAK-438 free base (Vonoprazan) is an orally active potassium-competitive acid blocker which inhibits H+, K+-ATPase activity with an IC50 of 19 nM. It is a novel potassium-competitive acid blocker that inhibits gastric H(+), K(+)-ATPase. In healthy Japanese male subjects, triple therapy with vonoprazan-amoxicillin-clarithromycin increased vonoprazan and clarithromycin exposure. The safety and tolerability profile of triple therapy with vonoprazan-amoxicillin-clarithromycin or vonoprazan-amoxicillin-metronidazole was favorable in this population^[3]. The healing rate of GERD (gastroesophageal reflux disease) and gastric ulcers by vonoprazan is more than 95 and 90%, respectively; also, it is effective in curing PPI (proton pump inhibitors)-resistant GERD. It is also effective in the eradication of clarithromycin-resistant H. pylori strains. All of these short-term studies show vonoprazan is safe and well-tolerated^[4]. Vonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing peptic ulcer recurrence during LDA (low-dose aspirin) therapy, had a similar long-term safety profile and was well tolerated^[5].